This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
Other namesD-16726; NSC-341952
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass351.402 g·mol−1
3D model (JSmol)

Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed.[1] It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials.[2][3] Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs,[4][5] and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414.[2][3] Zindoxifene was first described in 1984.[1]


  1. ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1300–. ISBN 978-1-4757-2085-3.
  2. ^ a b Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 170–. ISBN 978-3-0348-0664-0.
  3. ^ a b Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 32–. ISBN 978-0-12-416676-9.
  4. ^ Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 68–69. ISBN 978-3-642-58616-3.
  5. ^ International position paper on women's health and menopause : a comprehensive approach. DIANE Publishing. pp. 111–. ISBN 978-1-4289-0521-4.

External links